Medicalgorithmics, the Polish medtech company listed on the Warsaw Stock Exchange, has completed the integration of its ECG analysis software (DRP) powered by proprietary AI algorithms (DRAI) with two large technology partners. One of them is Wellysis, a leading Korean distributor and Samsung spin-off specializing in ECG monitoring projects, predictive analytics, and artificial intelligence solutions in healthcare. The innovative platform and AI algorithms have been fully integrated with Wellysis’ flagship S-Patch device (FDA-approved in the U.S.) and will now be available to all current and future clients of both companies — including in the United States.
The second implementation concerns a Canadian deep-tech company with whom Medicalgorithmics initiated cooperation in August. In total, the company has already integrated eight clients acquired through new partnerships formed this year.
Wellysis, a spin-off of Samsung, focuses on ECG monitoring, predictive analytics, and AI-based healthcare models. Its flagship product — S-Patch — is an innovative wireless, wearable ECG monitoring device supported by Samsung’s Smart Health Processor. Through its integration with Medicalgorithmics’ DRP and DRAI software, the system will be able to analyze patient data even more effectively in real time, expanding both the company’s offering and its potential customer base.
“We are very pleased to have delivered another set of integrations, especially with such a large and important partner as a Samsung spin-off. This integration increases our exposure to the U.S. market — the largest cardiology services market in the world. Since July, our innovative software and algorithms have already been used by the fifth-largest IDTF in the United States,”
says Dr. Kris Siemionow, CEO of Medicalgorithmics.
The agreement between Medicalgorithmics and the Samsung spin-off, signed in May this year, covers cooperation on the global market, with particular emphasis on the U.S., where the Polish medtech’s technology is gaining rapidly increasing recognition and demand. The Canadian deep-tech partner will use the DRP platform and DRAI algorithms in its proprietary textile-based Holter devices for at-home cardiac monitoring.
“We are also working on several additional large integrations, which will be rolled out gradually. So far, we have integrated eight out of the service providers and technology partners acquired in 2025, including our largest client. Both the Wellysis integration and the upcoming ones should significantly impact revenue levels in the coming quarters,”
adds Dr. Kris Siemionow.
Since the beginning of the year, the WSE-listed medtech company has been growing dynamically, acquiring new clients and reactivating existing ones. Medicalgorithmics has signed a record number of contracts (19 — more than in all of 2024), which has contributed to a significant increase in its share price. Since January, the company has doubled its market value, making it one of the best-performing investments on the Warsaw Stock Exchange in 2025.
Among the newly signed agreements are:
- a contract with one of the five largest U.S. IDTFs,
- a contract with a European IDTF,
- an agreement with a U.S. deep-tech company specializing in advanced materials, sensors, and AI integration,
- and two commercial VCAST agreements — one on the Turkish market and one on the strategic Scandinavian market.
Source: managerplus.pl
